ALSO NOTED: Schering-Plough licenses acadesine; Alchemia raises $15M; DOR action date extended; andmuch more...

> Schering-Plough has licensed acadesine, an adenosine regulating agent, from PeriCor Therapeutics. No terms were released. Release

> Australia's Alchemia announced a $15.2 million placement. Release

> DOR BioPharma announced that the action date for the FDA's review of its NDA for orBec for the treatment of gastrointestinal graft-versus-host disease has been extended to October 21, 2007. Release

> Par Pharmaceutical has settled a patent despite with Ortho-McNeil Pharmaceutical. Release

And Finally... A collaboration between the Scripps Research Institute and IBM to find new antidotes to flu before new mutations surface is making some initial progress. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.